Metastatic TNBC cannot wait

In this video podcast, Prof. Giuseppe Curigliano and Dr Javier Cortés explore how TROP2-directed antibody–drug conjugates (ADCs) are shaping 1st line treatment for metastatic triple-negative breast cancer (TNBC). 

Key clinical takeaways: 

• Earlier placement: TROPION-Breast02 and ASCENT-03 support 1st line TROP2 ADC use in defined patients who are not candidates for an ICI; ASCENT-04 supports SG plus pembrolizumab in the studied PD-L1-positive population  

• Individualised selection: Apply each trial to the appropriate patient. Consider disease characteristics, prior therapy, schedule and AE profile; avoid indirect comparisons between Dato-DXd and SG  

• Proactive safety: Translate the Dato-DXd and SG safety evidence into treatment-specific prevention, monitoring and escalation plans before dose 1  

You can also watch a video of the experts in conversation and download the accompanying transcript on our website: https://cor2ed.com/breast-cancer-connect/programmes/metastatic-tnbc 

Or watch on YouTube: https://youtu.be/3gr7g_IeRtU

Follow us on social media: 

LinkedIn: https://www.linkedin.com/company/breastcancerconnect/home/

X: https://x.com/BreastCaConnect

Instagram: https://www.instagram.com/cor2edmeded  

Subscribe to this channel to stay up to date with new medical education programmes as they’re released. 

This content is intended for healthcare professionals only. 

This podcast is supported by an Independent Education Grant from AstraZeneca  

This podcast is developed by cor2ed.com 

Published on October 2026